Alprazolam
- Generic Name
- Alprazolam
- Brand Names
- Niravam, Xanax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H13ClN4
- CAS Number
- 28981-97-7
- Unique Ingredient Identifier
- YU55MQ3IZY
- Background
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.
- Indication
Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.
Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.
- Associated Conditions
- Generalized Anxiety Disorder, Panic Disorder
Staccato Alprazolam Single Dose PK
- Conditions
- Healthy
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00444522
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
- Conditions
- Depressive Disorder and Anxiety Disorders
- Interventions
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00426608
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD
- Conditions
- Stress Disorder, Post Traumatic
- Interventions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Emory University
- Target Recruit Count
- 156
- Registration Number
- NCT00356278
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
- Conditions
- Panic DisorderGeneralized Anxiety Disorder
- Interventions
- Drug: SSRI/SNRI
- First Posted Date
- 2005-12-16
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 418
- Registration Number
- NCT00266409
- Locations
- 🇺🇸
Schwarz, Milwaukee, Wisconsin, United States
Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure
- Conditions
- Dental Anxiety
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT00245609
- Locations
- 🇬🇧
Pfizer Investigational Site, Sheffield, United Kingdom
A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety
- Conditions
- ANXIETY
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00139854
- Locations
- 🇺🇸
Schwarz, Milwaukee, Wisconsin, United States
Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety
- Conditions
- Anxiety DisorderPanic Disorder
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 80
- Registration Number
- NCT00004373
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.